BMS-833923_1059734-66-5_DataSheet_MedChemExpress

P d D Sh Product Name:

BMS-833923CAS No.:

1059734-66-5Cat. No.:

HY-13809

Product Data Sheet

MWt:

473.57Formula:

C30H27N5O Purity :>98%

Solubility:

DMSO

Mechanisms:

Biological Activity:

BMS-833923 (XL-139) is an orally bioavailable small-molecule inhibitor of Smoothened with

Pathways:Wnt/Hedgehog/Notch; Target:Smo ()y potential antineoplastic activity; inhibits BODIPY cyclopamine binding to SMO in a dose-dependent

manner with an IC50 of 21 nM.

IC50 Value: 6-35 nM [1]

Target: Smoothened SMO antagonist BMS-833923 inhibits the sonic hedgehog (SHH) pathway protein SMO, which may

result in a suppression of the SHH signaling pathway.in vitro: In vitro, BMS-833923 inhibits the expression of downstream effectors in the HH pathway (GLI1 and PTCH1) in cell lines that express wild-type SMO and those which express activated t t f f SMO (IC50l f 635M)I FACS b d bi di BMS 833923References:

[1]. Steven B, et al. Abstract B192: Preclinical characterization of BMS-833923 (XL139), a hedgehog (HH) pathway inhibitor in early clinical development. Molecular Cancer Therapeutics: December 2009;Volume 8Issue 12Supplement 1mutant forms of SMO (IC50values of 6-35 nM). In FACS-based binding assays, BMS-833923inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner with an IC50 of 21 nM

[1]. in vivo: Pharmacodynamic studies show that BMS-833923 robustly inhibits HH pathway activity with 2009; Volume 8, Issue 12, Supplement 1.

Caution: Not fully tested. For research purposes only

Medchemexpress LLC

https://www.360docs.net/doc/c67231777.html,

18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S A

E m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m